Abstract
Introducton: Ticlopidine is an antiplatelet agent available from several decades. Its most important adverse drug reactions (ADRs) involve haematological system. Our aim was to evaluate the safety profile of ticlopidine in the real life, on the basis of spontaneous ADR reporting.
Materials and Methods: Spontaneous reports from 8 Italian Regions collected from 1990 to March 2007 were analysed. According to WHO Adverse Reaction Terminology for causality assessment only “certain”, “probable” or “possible” ADRs were included. Association between drugs and any ADR was assessed by using the case/non-case methodoloy. Reporting odds ratio (ROR) was computed as a measure of disproportionality.
Results: Overall, 478 reports concerning ticlopidine were analysed. The system organ classes with significant disproportionality for ticlopidine included White Cell Disorders (ROR=22.43, 95% CI 18.54–27.12), Red Cell Disorders (8.22; 6.03-11.18), Liver And Biliary System (6.67; 5.35–8.32), Platelet, Bleeding & Clotting (6.59; 5.16-8.40). Fifteen percent of the ADRs occurred beyond the first three months of ticlopidine therapy. In 386 reports (80.7%), ticlopidine was the only suspected drug.
Conclusion: Safety profile of ticlopidine can be considered well-established in terms of ADRs type but their frequency and severity continue to be higher in its current use. Since this drug is still widely used in Italy, both healthcare providers and patients should be aware of its ADRs. More specifically, patients should be regularly monitored during the whole period of use and not only in the first months of treatment.
Keywords: Adverse drug reactions, case-non case study, spontaneous reporting, ticlopidine.
Current Drug Safety
Title:Ticlopidine Safety Profile: A Case/Non-Case Study on the Basis of the Spontaneous ADRs Reporting in Italy
Volume: 7 Issue: 2
Author(s): Domenico Motola, Chiara Biagi, Roberto Leone, Mauro Venegoni, Francesco Lapi, Paola Cutroneo, Antonio Vargiu, Roberto Bonaiuti, Nicola Montanaro and Alberto Vaccheri
Affiliation:
Keywords: Adverse drug reactions, case-non case study, spontaneous reporting, ticlopidine.
Abstract: Introducton: Ticlopidine is an antiplatelet agent available from several decades. Its most important adverse drug reactions (ADRs) involve haematological system. Our aim was to evaluate the safety profile of ticlopidine in the real life, on the basis of spontaneous ADR reporting.
Materials and Methods: Spontaneous reports from 8 Italian Regions collected from 1990 to March 2007 were analysed. According to WHO Adverse Reaction Terminology for causality assessment only “certain”, “probable” or “possible” ADRs were included. Association between drugs and any ADR was assessed by using the case/non-case methodoloy. Reporting odds ratio (ROR) was computed as a measure of disproportionality.
Results: Overall, 478 reports concerning ticlopidine were analysed. The system organ classes with significant disproportionality for ticlopidine included White Cell Disorders (ROR=22.43, 95% CI 18.54–27.12), Red Cell Disorders (8.22; 6.03-11.18), Liver And Biliary System (6.67; 5.35–8.32), Platelet, Bleeding & Clotting (6.59; 5.16-8.40). Fifteen percent of the ADRs occurred beyond the first three months of ticlopidine therapy. In 386 reports (80.7%), ticlopidine was the only suspected drug.
Conclusion: Safety profile of ticlopidine can be considered well-established in terms of ADRs type but their frequency and severity continue to be higher in its current use. Since this drug is still widely used in Italy, both healthcare providers and patients should be aware of its ADRs. More specifically, patients should be regularly monitored during the whole period of use and not only in the first months of treatment.
Export Options
About this article
Cite this article as:
Motola Domenico, Biagi Chiara, Leone Roberto, Venegoni Mauro, Lapi Francesco, Cutroneo Paola, Vargiu Antonio, Bonaiuti Roberto, Montanaro Nicola and Vaccheri Alberto, Ticlopidine Safety Profile: A Case/Non-Case Study on the Basis of the Spontaneous ADRs Reporting in Italy, Current Drug Safety 2012; 7 (2) . https://dx.doi.org/10.2174/157488612802715717
DOI https://dx.doi.org/10.2174/157488612802715717 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Meet Our Editorial Board Member
Current Cardiology Reviews Vasorelaxation Caused by Cannabinoids: Mechanisms in Different Vascular Beds
Current Vascular Pharmacology The Role of Coronary Angioplasty in the Management of Patients with Stable Coronary Artery Disease
Cardiovascular & Hematological Disorders-Drug Targets Cardiovascular Implantable Electronic Device Infections: Risk Scoring and Role of Antibiotic Envelope in Prevention
Recent Advances in Cardiovascular Drug Discovery (Discontinued) In Vitro Dissolution Testing of Drug-Eluting Stents
Current Pharmaceutical Biotechnology The Failing Heart in Pediatric Dilated Cardiomyopathy Caused by Excessive Water Drinking: A Case Report and Brief Review
New Emirates Medical Journal Essential Hypertension: Translating Pathophysiology into Pharmacogenomics
Current Pharmacogenomics The Metabolic Syndrome and Vascular Disease in Asia
Cardiovascular & Hematological Disorders-Drug Targets Meet Our Regional Editor:
Current Drug Discovery Technologies Ezetimibe and other Azetidinone Cholesterol Absorption Inhibitors
Current Topics in Medicinal Chemistry Enriching One’s Environment in the Face of Cognitive and Functional Loss
Current Neurovascular Research Atherogenic Index of Plasma in Women with Rheumatoid Arthritis and Systemic Lupus Erythematosus: A 10-Year Potential Predictor of Cardiovascular Disease
Current Rheumatology Reviews Platelet-Derived Exosomes Affect the Proliferation and Migration of Human Umbilical Vein Endothelial Cells Via miR-126
Current Vascular Pharmacology Garlic for Cardiovascular Disease: Prevention or Treatment?
Current Pharmaceutical Design Adenosine in the Central Nervous System: Effects on Neurotransmission and Neuroprotection
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Dynamic Role of Microparticles in Type 2 Diabetes Mellitus
Current Diabetes Reviews Editorial [Hot Topic: Current Antithrombotic Management of ST Elevation Acute Coronary Syndromes in the Cath Lab – A Paradigm Shift (Guest Editor: Bernardo Cortese)]
Current Vascular Pharmacology Updates on HCN Channels in the Heart: Function, Dysfunction and Pharmacology
Current Drug Targets Basilar Apex Aneurysms in the Setting of Carotid Artery Stenosis: Case Series and Angiographic Anatomic Study
Current Neurovascular Research The Heart in Sepsis: From Basic Mechanisms to Clinical Management
Current Vascular Pharmacology